[Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
OBJECTIVE
To evaluate the clinical usefulness of CYFRA21-1 as a serum tumor marker in diagnosis, evaluation of clinical status and prognosis of patients with non-small-cell lung cancer (NSCLC).


METHODS
CYFRA21-1 in 126 serum samples of NSCLC patients was measured by radioimmunoassay. Of the 126 samples, 71 were collected before treatment, 29 at two weeks after operation, and 26 after 15-18 months follow-up.


RESULTS
CYFRA21-1 was positive in 49.3% of the NSCLC patients who had not received any treatment. The positive rate was 69.2% for squamous-cell carcinoma, and 25.0% for adenocarcinoma. The serum level of CYFRA21-1 was significantly higher in squamous-cell carcinoma than in adenocarcinoma (P < 0.0001). The serum level of CYFRA21-1 well correlated and increased with TNM staging (P = 0.0001). The level decreased significantly within two weeks after surgical operation in 29 cases (P = 0.0005). On follow up for 15-18 months, no change in CYFRA21-1 level was observed in 16 patients whose disease was stable, while there was significant increase in 10 patients with progressive disease.


CONCLUSIONS
CYFRA21-1 is a soluble fragment of cytokeratin 19 in serum of patients with NSCLC. It can be used as a useful tumor marker of NSCLC.
Tan
Y
Y
Department of Oncology, Daping Hospital, Third Military Medical University, Chongqing 400042.
Zhang
P
P
Zheng
C
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D002648:Child; D005260:Female; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; C102012:antigen CYFRA21.1; D007633:Keratins